Skip to main content
TipRanks
Go Ultimate75% OFF

Botanix Pharmaceuticals Limited (BOT) AI Stock Analysis

174 Followers
AU:BOT

Botanix Pharmaceuticals Limited

(ASX:BOT)

Select Model
Rating:42Neutral
Price Target:AUD 0.01â–²(0.00% Upside)
Action:reiterated
Date:11/07/26

The score is mainly driven by weak financial quality (large, persistent losses and substantial cash burn despite strong revenue growth) and bearish technicals (price below major moving averages with negative MACD). Valuation contributes limited support because the company is loss-making (negative P/E) and no dividend yield is provided.

Positive Factors
Revenue GrowthRapid revenue growth indicates increasing commercial traction and expanding demand for the company’s offerings. If this momentum persists, it could improve operating leverage, support broader market adoption, and provide a stronger foundation for eventually funding development from internal resources.
Negative Factors
Persistent UnprofitabilityPersistent operating and net losses show that revenue growth has not yet translated into an economically sustainable business model. Deeply negative gross profit also raises uncertainty around margin durability, leaving the company dependent on future improvement in commercial performance and cost absorption.

Botanix Pharmaceuticals Limited (BOT) vs. iShares MSCI Australia ETF (EWA)

-100%-75%-50%-25%0%25%AU:BOT-91.67%EWA+14.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 21.92M
Dividend Yield
―
Average Volume (3M)
7.78M
Price to Earnings (P/E)
-0.3
Beta (1Y)
1.04
Revenue Growth
499.47%
EPS Growth
31.20%
Country
Australia
Employees
11
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Botanix Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespr...

Botanix Pharmaceuticals Limited Earnings Call Summary

Earnings Call Date:Feb 27, 2026(Q2-2026)|% Change Since:-82.14%|Next Earnings Date:Mar 03, 2027
Earnings Call SentimentNeutral

The call conveyed strong commercial momentum — rapid prescription growth, meaningful revenue ramp, a high‑performing fulfillment platform (fill rates ~2.5x industry), positive physician adoption signals (90% expect to increase prescribing) and an attractive IP runway to 2040. Counterbalancing this progress are sizeable operating losses (adjusted EBITDA loss $26.1M; loss before tax $33.2M), material near‑term API purchase obligations and reliance on a partially‑completed capital raise and a single API supplier. Management has identified clear catalysts (alternate API supplier to cut COGS 25%–40%, platform scalability, and $45M committed raise) but execution and funding are key near‑term risks. Overall, the call was upbeat on commercial execution but sober about cash, supply and funding needs.

Positive Updates

Rapid prescription and revenue growth
62,500 prescriptions shipped in the first 11 months post‑launch; 45,800 prescriptions in H1 FY2026 vs 16,800 in the prior half (171% increase). Net revenue rose from $5.1M in the second half of FY2025 to $16.2M in H1 FY2026 (219% increase). Total revenue for H1 FY2026 was $16.5M (versus $0.346M prior corresponding period).

Negative Updates

Substantial operating losses and cash burn
Adjusted EBITDA loss for H1 FY2026 was $26.1M and loss before tax was $33.2M. Direct operating expenses totaled $36.6M (including $24.7M sales & marketing and $7M internal employee costs). Company closed the period with $31.6M cash and equivalents, creating sensitivity to continuing funding and execution.

Company Guidance

Management guided that Botanix will scale Sofdra and its SendRx fulfillment platform while pursuing cost and supply improvements: since launch Sofdra has shipped 62,500 prescriptions (first 11 months) generating almost $100M gross revenue and $21.2M net revenue, and in H1 FY26 prescriptions rose 171% to 45,800 (from 16,800) with net revenue up 219% to $16.2M (total revenue $16.5M incl. royalties); fill/adherence metrics exceed industry benchmarks (~2.5x), the U.S. sales force is 50 reps (expanded Oct‑2025), cash was $31.6M at period end, adjusted EBITDA loss was $26.1M and loss before tax $33.2M, with materials $6.0M, sales & marketing $24.7M, employee costs $7.0M and G&A $3.2M. They have firm commitments for a $45M raise ($14.9M received) with proceeds allocated roughly $12M API/manufacturing, $4M alternate‑API setup, $13.5M marketing, $13M operating/working capital and $2.5M fees, are negotiating to defer near‑term API purchases (Mar/Apr 2026 and Jan 2027), and expect an alternate API to cut COGS 25–40% and improve gross‑to‑net toward ~30–40%; Sofdra’s IP runs to 2040 and the TAM is ~10M patients (≈3.7M actively seeking treatment), with management expecting revenue growth to outpace costs as adoption and payer coverage expand.

Botanix Pharmaceuticals Limited Financial Statement Overview

Summary

Revenue growth is strong (2026 up ~57% to ~34.5M), but profitability and cash generation are very weak. Gross profit turned deeply negative in 2026, EBIT and net income are materially negative, and operating/free cash flow remain heavily negative (large ongoing cash burn), implying continued reliance on external funding. The balance sheet is comparatively steadier with reduced debt and a remaining equity cushion, but ongoing losses pressure equity over time.

Income Statement

22Negative

Balance Sheet

54Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue34.51M34.51M5.79M601.82K914.97K2.75M
Gross Profit-59.43M-59.43M2.02M-6.12M-3.05M-7.54M
EBITDA-68.12M-69.31M-80.65M-15.25M-12.63M-15.74M
Net Income-69.77M-69.77M-86.40M-13.87M-9.15M-13.17M
Balance Sheet
Total Assets105.98M105.98M129.10M112.46M24.84M14.04M
Cash, Cash Equivalents and Short-Term Investments36.63M36.63M64.97M79.31M10.25M7.29M
Total Debt14.74M14.74M32.51M00122.41K
Total Liabilities42.45M42.45M47.80M3.73M1.88M5.89M
Stockholders Equity63.52M63.52M81.30M108.73M22.95M8.15M
Cash Flow
Free Cash Flow-64.60M-64.60M-78.87M-26.13M-19.13M-14.11M
Operating Cash Flow-64.60M-64.60M-78.58M-8.13M-12.07M-11.18M
Investing Cash Flow-408.96K-408.96K-1.05M-18.00M-7.05M-2.92M
Financing Cash Flow36.58M36.58M65.36M95.10M22.03M-152.41K

Botanix Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.01

Price Trends

50DMA0.02Negative
100DMA0.02Negative
200DMA0.03Negative

Market Momentum

MACD-0.00Negative
RSI33.47Neutral
STOCH43.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BOT, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 33.47 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BOT.

Botanix Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:BOT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:CUVAU:CUV77OutperformAUD 372.59M10.8513.00%0.68%-1.05%-6.74%
AU:ZLDAU:ZLD52NeutralAUD 5.95M-1.5680.84%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:ACRAU:ACR47NeutralAUD 5.82M-6.43-45.29%―290.25%92.05%
AU:RCEAU:RCE46NeutralAUD 114.72M-7.2484.67%――42.51%
AU:SPLAU:SPL43NeutralAUD 200.41M-24.27-42.35%―145.32%25.75%
AU:BOTAU:BOT42NeutralAUD 27.63M-0.31-118.74%―499.47%31.20%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%AU:BOTAU:ACRAU:CUVAU:SPLAU:ZLDAU:RCEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:BOT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:BOTBotanix Pharmaceuticals Limited0.01-0.11-91.67%
AU:ACRAcrux Limited0.01-0.00-33.33%
AU:CUVClinuvel Pharmaceuticals Limited7.38-3.43-31.76%
AU:SPLStarpharma Holdings Limited0.410.025.33%
AU:ZLDZelira Therapeutics Ltd.0.500.1333.33%
AU:RCERecce Pharmaceuticals Ltd.0.38-0.07-14.77%

Botanix Pharmaceuticals Limited Corporate Events

Botanix Reports Cessation of 31.8 Million Securities

Nov 6, 2026

Botanix Pharmaceuticals Ltd reported the cessation of 31,816,666 conditional securities on November 1, 2026, comprising options and performance rights across five security classes. The securities lapsed because their conditions were not satisfied or...

Botanix sets 2026 AGM to vote on pay report and director re-election

Oct 29, 2026

Botanix Pharmaceuticals has called its annual general meeting for 30 November 2026 in Perth, where shareholders will review the company’s financial statements for the year ended 30 June 2026 and associated governance reports. The meeting will also co...

Botanix Pharmaceuticals Seeks ASX Quotation for New Share Issue

Oct 28, 2026

Botanix Pharmaceuticals has applied to the ASX for quotation of 1,125,000 new ordinary fully paid shares, to be issued on October 28, 2026. The additional securities arise from the exercise of options or conversion of other instruments, modestly incr...

Botanix’s Latest Investor Update Emphasises Risk and Regulatory Caution

Oct 26, 2026

Botanix Pharmaceuticals has released an investor update presentation dated 27 October 2026, outlining high-level information for current and prospective shareholders. The document is framed as a general summary, directing investors to ASX filings for...

Botanix Pharmaceuticals Appoints New Director With No Current Shareholdings

Oct 19, 2026

Botanix Pharmaceuticals Limited has appointed Mr Andrew Bickley as a director effective 18 October 2026, according to an initial director’s interest notice lodged with the ASX. At the time of appointment, Bickley holds no relevant interests in the co...

Botanix Discloses Director Daniel Sharp’s Exit and Indirect Holdings

Oct 19, 2026

Botanix Pharmaceuticals has disclosed that director Daniel Sharp ceased to be a director on 17 October 2026, in line with ASX listing rule requirements. The company reported that Sharp held no securities as a registered holder, but had indirect inter...

Botanix refreshes board with interim Australian directors after resignations

Oct 19, 2026

Botanix Pharmaceuticals has announced the immediate resignation of Australian resident Non-Executive Directors Dr Stewart Washer and Mr Danny Sharp, triggering a board renewal process at the dermatology-focused ASX-listed company. In response, Compan...

Botanix Sets 2026 AGM Date as Governance Milestones Align with Sofdra Push

Oct 2, 2026

Botanix Pharmaceuticals has scheduled its 2026 Annual General Meeting for 9:30 a.m. AWST on 30 November 2026 at BDO’s offices in Perth, Western Australia. The meeting will include the re-election of directors, with nomination deadlines set for 5:00 p...

Botanix Director Increases Equity Stake via Performance Rights Conversion

Sep 23, 2026

Botanix Pharmaceuticals has disclosed a change in director Vincent Ippolito’s interests, following the exercise of performance rights granted under the company’s employee incentive plan. Ippolito converted 4 million performance rights into fully paid...

Botanix seeks ASX quotation for 24.9 million new shares

Sep 23, 2026

Botanix Pharmaceuticals has applied for quotation on the ASX of 24,933,333 new ordinary fully paid shares, which were issued on 22 September 2026. The application indicates an expansion of the company’s listed share capital, potentially providing add...

S&P Dow Jones Indices Unveils September 2026 Rebalance of S&P/ASX Benchmarks

Sep 4, 2026

S&P Dow Jones Indices has announced its September 2026 quarterly rebalance of the S&P/ASX indices, with changes taking effect before trading opens on September 21. The S&P/ASX 20 will remain unchanged, while the S&P/ASX 50 will see Mineral Resources...

Botanix Updates Director Patricia Walker’s Equity Holdings After Option Expiry

Aug 31, 2026

Botanix Pharmaceuticals has disclosed a change in director Dr Patricia Walker’s interests, following the expiry and cancellation of 1,000,000 unquoted options exercisable at $0.145 that were due to expire on 22 August 2026. After the change, Dr Walke...

Botanix Pharmaceuticals Options Lapse, Streamlining Capital Structure

Aug 31, 2026

Botanix Pharmaceuticals Ltd has reported the lapse of 1,000,000 options, each exercisable at $0.145 and expiring on 22 August 2026, which ceased on 25 August 2026 after remaining unexercised. The expiry modestly reduces the company’s pool of potentia...

Botanix files updated ASX corporate governance statement for 2026

Aug 26, 2026

Botanix Pharmaceuticals has lodged its updated corporate governance statement for the financial year ended 30 June 2026, confirming it is available on the company’s website and has been approved by the board as at 26 August 2026. The accompanying App...

Botanix Revenue Surges on Sofdra Launch as Loss Narrows

Aug 26, 2026

Botanix Pharmaceuticals reported a sharp increase in revenue for the year ended 30 June 2026, with customer sales rising 487% to $33.8 million, driven by the first full year of Sofdra’s commercial launch in the United States and royalty income from p...

Botanix Issues 14 Million Unquoted Performance Rights Under Incentive Plan

Aug 14, 2026

Botanix Pharmaceuticals has notified the market of the issue of 14,000,000 unquoted performance rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on August 11, 2026 and undersc...

Botanix Pharmaceuticals Adds 2.3 Million Shares to ASX Quotation

Aug 14, 2026

Botanix Pharmaceuticals has applied for quotation of 2,300,000 additional ordinary fully paid shares on the ASX, with an issue date of Aug. 13, 2026. The application is lodged under Appendix 2A of the ASX Listing Rules, confirming the securities will...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026